The Development of Disease-Modifying Therapies for Osteoarthritis (DMOADs): The Evidence to Date.
Ontology highlight
ABSTRACT: Osteoarthritis (OA) is a complex heterogeneous articular disease with multiple joint tissue involvement of varying severity and no regulatory-agency-approved disease-modifying drugs (DMOADs). In this review, we discuss the reasons necessitating the development of DMOADs for OA management, the classifications of clinical phenotypes or molecular/mechanistic endotypes from the viewpoint of targeted drug discovery, and then summarize the efficacy and safety profile of a range of targeted drugs in Phase 2 and 3 clinical trials directed to cartilage-driven, bone-driven, and inflammation-driven endotypes. Finally, we briefly put forward the reasons for failures in OA clinical trials and possible steps to overcome these barriers.
SUBMITTER: Oo WM
PROVIDER: S-EPMC8273751 | biostudies-literature |
REPOSITORIES: biostudies-literature
ACCESS DATA